Analyzing BATM Advanced Communications (OTCMKTS:BTAVF) & Orchestra BioMed (NASDAQ:OBIO)

BATM Advanced Communications (OTCMKTS:BTAVF) and Orchestra BioMed (NASDAQ:OBIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares BATM Advanced Communications and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BATM Advanced Communications	N/A	N/A	N/A
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Institutional and Insider Ownership

53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for BATM Advanced Communications and Orchestra BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BATM Advanced Communications	0	0	0	0	0.00
Orchestra BioMed	1	1	5	0	2.57

Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 218.50%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than BATM Advanced Communications.

Earnings & Valuation

This table compares BATM Advanced Communications and Orchestra BioMed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BATM Advanced Communications	N/A	N/A	N/A	N/A	N/A
Orchestra BioMed	$33.48 million	7.64	-$52.70 million	($0.97)	-4.40

BATM Advanced Communications has higher earnings, but lower revenue than Orchestra BioMed.

Summary

Orchestra BioMed beats BATM Advanced Communications on 6 of the 9 factors compared between the two stocks.

About BATM Advanced Communications

BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in Networking and Cyber, and Bio-Medical divisions. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization, carrier ethernet and MPLS access solutions, and cyber network monitoring. It also offers software services, such as training and technical support, laboratory service and maintenance; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.